Completed PHASE1 INTERVENTIONAL 4-arm NCT02652377

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC)

Sponsor: Enanta Pharmaceuticals, Inc

Conditions Hepatitis C

Interventions EDP-494 Placebo

Updated 7 times since 2017 Last updated: Jan 20, 2017 Started: Jan 10, 2016 Primary completion: Dec 27, 2016 Completion: Dec 27, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02652377, this PHASE1 trial focuses on Hepatitis C and remains completed. Sponsored by Enanta Pharmaceuticals, Inc, it has been updated 7 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Data source: Enanta Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Auckland, New Zealand